University of Pittsburgh Cancer Institute (UPCI) researchers have uncovered a technique to halt the growth of cancer cells, a discovery that led them to a potential new anti-cancer therapy. When deprived of a key protein, some cancer cells are unable to properly divide, a finding described in the cover story of the February 2013 issue of the Journal of Cell Science and first published online on .September 26, 2012 in that journal. "This is the first time anyone has explained how altering this protein at a key stage in cell reproduction can stop cancer growth," said Bennett Van Houten, Ph.D., the Richard M. Cyert Professor of Molecular Pharmacology at UPCI and senior author of the research paper. "Our hope is that this discovery will spur the development of a new type of cancer drug that targets this process and could work synergistically with existing drugs." All cells have a network of mitochondria, which are tiny structures inside cells that are essential for energy production and metabolism. Dynamin-related protein 1 (Drp1) helps mitochondria undergo fission, a process by which they split themselves into two new mitochondria. In breast or lung cancer cells made to be deficient in Drp1, the researchers observed a huge network of highly fused mitochondria. These cancer cells appear to have stalled during a stage in cell division called G2/M. Unable to divide into new cells, the cancer growth stops. Those cells that do try to divide literally tear their chromosomes apart, causing more stress for the cell. The cover of the Journal of Cell Science includes a colorful image of a breast cancer cell deficient in Drp1 that is stuck during the process of separating its chromosomes into two identical sets to be divided among two new cells. Lead author Wei Qian, Ph.D., a postdoctoral fellow in Dr.
Login Or Register To Read Full Story